Travere Therapeutics Inc Cash Flow Conversion Efficiency
Travere Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Travere Therapeutics Inc (TVTX) has a cash flow conversion efficiency ratio of 2.368x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($58.07 Million) by net assets ($24.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Travere Therapeutics Inc (2010–2025)
Cash flow conversion efficiency of Travere Therapeutics Inc from 2010 to 2025. This chart illustrates how Travere Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Travere Therapeutics Inc stock price for real-time trading data and today's change.
Travere Therapeutics Inc Cash Flow Conversion Ratio Explained
Travere Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Travere Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Travere Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Travere Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Moneta Money Bank AS
PR:MONET
|
-0.209x |
|
EFG International AG
SW:EFGN
|
0.556x |
|
Hannon Armstrong Sustainable Infrastructure Capital Inc
NYSE:HASI
|
6.160x |
|
Shenzhen Sunlord Electronics Co Ltd
SHE:002138
|
0.052x |
|
Vietnam Rubber Group Ltd
VN:GVR
|
0.040x |
|
Sai Gon Thuong Tin Commercial Joint Stock Bank
VN:STB
|
0.272x |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
0.066x |
|
RTL Group SA
F:RRTL
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Travere Therapeutics Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of Travere Therapeutics Inc from 2010 to 2025. Review Travere Therapeutics Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $114.83 Million | $37.78 Million | 0.329x | +108.19% |
| 2024-12-31 | $59.08 Million | $-237.47 Million | -4.020x | -188.27% |
| 2023-12-31 | $200.81 Million | $-280.02 Million | -1.394x | +67.92% |
| 2022-12-31 | $42.85 Million | $-186.29 Million | -4.347x | -8779.16% |
| 2021-12-31 | $302.11 Million | $-14.79 Million | -0.049x | +75.81% |
| 2020-12-31 | $211.21 Million | $-42.74 Million | -0.202x | +23.11% |
| 2019-12-31 | $221.20 Million | $-58.21 Million | -0.263x | -235.59% |
| 2018-12-31 | $318.25 Million | $-24.96 Million | -0.078x | -410.52% |
| 2017-12-31 | $293.13 Million | $7.40 Million | 0.025x | +587.00% |
| 2016-12-31 | $307.77 Million | $-1.60 Million | -0.005x | -180.79% |
| 2015-12-31 | $299.97 Million | $-554.00K | -0.002x | -100.15% |
| 2014-12-31 | $-37.25 Million | $-45.85 Million | 1.231x | +28.14% |
| 2013-12-31 | $-18.31 Million | $-17.59 Million | 0.961x | +19.61% |
| 2012-12-31 | $-3.41 Million | $-2.74 Million | 0.803x | +103283.92% |
| 2011-12-31 | $-63.08K | $-49.00 | 0.001x | -93.21% |
| 2010-12-31 | $-60.26K | $-689.00 | 0.011x | -- |
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola a… Read more